Short-acting β
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
25
10
2022
accepted:
11
01
2023
medline:
27
4
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
epublish
Résumé
Prescription of three or more short-acting β This study analysed data on children and adolescents with asthma in three age cohorts: 1‒5 years, 6‒11 years and 12‒17 years from the Clinical Practice Research Datalink Aurum database for the period 1 January 2007 to 31 December 2019. Associations between SABA prescriptions (three or more Overall 48 560, 110 091 and 111 891 paediatric patients with asthma were aged 1‒5, 6‒11 and 12‒17 years, respectively. During the baseline period, 22 423 (46.2%), 42 137 (38.3%) and 40 288 (36.0%) in these three age cohorts, respectively, were prescribed three or more SABA canisters per year. Across all age ranges, the rate of future asthma exacerbations in those prescribed three or more In children, higher SABA prescriptions at baseline were associated with increased future exacerbation rates. These findings highlight the need for monitoring prescription of three or more SABA canisters per year to identify children with asthma at risk of exacerbations.
Sections du résumé
Background
UNASSIGNED
Prescription of three or more short-acting β
Methods
UNASSIGNED
This study analysed data on children and adolescents with asthma in three age cohorts: 1‒5 years, 6‒11 years and 12‒17 years from the Clinical Practice Research Datalink Aurum database for the period 1 January 2007 to 31 December 2019. Associations between SABA prescriptions (three or more
Results
UNASSIGNED
Overall 48 560, 110 091 and 111 891 paediatric patients with asthma were aged 1‒5, 6‒11 and 12‒17 years, respectively. During the baseline period, 22 423 (46.2%), 42 137 (38.3%) and 40 288 (36.0%) in these three age cohorts, respectively, were prescribed three or more SABA canisters per year. Across all age ranges, the rate of future asthma exacerbations in those prescribed three or more
Conclusion
UNASSIGNED
In children, higher SABA prescriptions at baseline were associated with increased future exacerbation rates. These findings highlight the need for monitoring prescription of three or more SABA canisters per year to identify children with asthma at risk of exacerbations.
Identifiants
pubmed: 37101737
doi: 10.1183/23120541.00571-2022
pii: 00571-2022
pmc: PMC10123517
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: A. Morgan and C. Kallis have nothing to declare. E. Maslova, T.N. Tran and R.J.P. van der Valk are employees of AstraZeneca and hold AstraZeneca shares. R.J.P. van der Valk holds shares in GlaxoSmithKline. G. Roberts and I. Sinha received consultancy from AstraZeneca to their institutions for this work. J.K. Quint reports grants from AUK-BLF and The Health Foundation; grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Bayer; and grants from Chiesi, outside the submitted work. J.K. Quint's research group received funding from AstraZeneca for this work.
Références
Eur Respir J. 2019 Jul 18;54(1):
pubmed: 31048346
Eur Respir J. 2019 Apr 4;53(4):
pubmed: 30948504
Thorax. 2018 Sep;73(9):813-824
pubmed: 29871982
Respir Res. 2019 Aug 14;20(1):183
pubmed: 31412856
JAMA Netw Open. 2022 Mar 01;5(3):e220615
pubmed: 35230437
BMC Public Health. 2012 Mar 19;12:204
pubmed: 22429515
Pharmacol Res. 2020 Oct;160:105189
pubmed: 32911071
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211042534
pubmed: 34587829
Ann Allergy Asthma Immunol. 2012 Dec;109(6):403-7
pubmed: 23176877
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889114
Eur Respir J. 2022 May 5;59(5):
pubmed: 34561293
Adv Ther. 2020 Mar;37(3):1124-1135
pubmed: 31981105
Medicare Medicaid Res Rev. 2013 Dec 16;3(4):
pubmed: 24834366
Ann Allergy Asthma Immunol. 2012 Feb;108(2):81-7
pubmed: 22289725
Am J Manag Care. 2003 Aug;9(8):538-47
pubmed: 12921231
Eur Respir J. 2018 Jan 4;51(1):
pubmed: 29301922
Health Technol Assess. 2016 Dec;20(93):1-154
pubmed: 28005003
BMJ Evid Based Med. 2022 Jun;27(3):178-184
pubmed: 34282031
NPJ Prim Care Respir Med. 2018 May 21;28(1):16
pubmed: 29785053
Pediatr Allergy Immunol. 2022 Nov;33(11):e13885
pubmed: 36433853
Lung India. 2019 Mar-Apr;36(2):131-138
pubmed: 30829247
NPJ Prim Care Respir Med. 2021 Jan 29;31(1):3
pubmed: 33514720
Chest. 2006 Dec;130(6):1733-43
pubmed: 17166990
Pediatrics. 2013 Jan;131(1):e136-43
pubmed: 23209109
Respir Care. 2015 Mar;60(3):455-68
pubmed: 25118311
Ann Allergy Asthma Immunol. 2015 May;114(5):385-92
pubmed: 25840499
Adv Ther. 2020 Oct;37(10):4190-4208
pubmed: 32720299
Lancet. 2018 Jan 27;391(10118):350-400
pubmed: 28911920
Chest. 2017 Mar;151(3):612-618
pubmed: 27815152
Eur Respir J. 2015 Feb;45(2):396-407
pubmed: 25323234